VTRS
NASDAQ · Pharmaceuticals
Viatris Inc
$17.20
+0.25 (+1.47%)
Financial Highlights (FY 2026)
Revenue
13.67B
Net Income
-3,359,009,661
Gross Margin
39.5%
Profit Margin
-24.6%
Rev Growth
-4.2%
D/E Ratio
0.98
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 39.5% | 39.5% | 35.8% | 35.8% |
| Operating Margin | -19.3% | -17.4% | 29.8% | 37.8% |
| Profit Margin | -24.6% | -23.4% | 27.9% | 27.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 13.67B | 14.26B | 3.47B | 3.37B |
| Gross Profit | 5.40B | 5.64B | 1.24B | 1.20B |
| Operating Income | -2,642,929,215 | -2,482,918,886 | 1.03B | 1.27B |
| Net Income | -3,359,009,661 | -3,155,645,819 | 966.90M | 917.66M |
| Gross Margin | 39.5% | 39.5% | 35.8% | 35.8% |
| Operating Margin | -19.3% | -17.4% | 29.8% | 37.8% |
| Profit Margin | -24.6% | -23.4% | 27.9% | 27.3% |
| Rev Growth | -4.2% | -4.2% | -2.8% | +22.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 4.69B | 4.69B | 4.37B | 3.63B |
| Total Equity | 4.79B | 4.79B | 12.59B | 11.78B |
| D/E Ratio | 0.98 | 0.98 | 0.35 | 0.31 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 30.99M | 30.73M | 1.51B | 1.62B |
| Free Cash Flow | — | — | 925.81M | 1.00B |